CA2106368A1 - Methodes et compositions pour le traitement de la maladie angiogenique - Google Patents

Methodes et compositions pour le traitement de la maladie angiogenique

Info

Publication number
CA2106368A1
CA2106368A1 CA002106368A CA2106368A CA2106368A1 CA 2106368 A1 CA2106368 A1 CA 2106368A1 CA 002106368 A CA002106368 A CA 002106368A CA 2106368 A CA2106368 A CA 2106368A CA 2106368 A1 CA2106368 A1 CA 2106368A1
Authority
CA
Canada
Prior art keywords
rpf4
treatment
synthetic
recombinant
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002106368A
Other languages
English (en)
Inventor
Theodore E. Maione
Richard J. Sharpe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Repligen Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2106368A1 publication Critical patent/CA2106368A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002106368A 1992-01-16 1993-01-19 Methodes et compositions pour le traitement de la maladie angiogenique Abandoned CA2106368A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82237892A 1992-01-16 1992-01-16
US822,378 1992-01-16

Publications (1)

Publication Number Publication Date
CA2106368A1 true CA2106368A1 (fr) 1993-07-17

Family

ID=25235857

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002106368A Abandoned CA2106368A1 (fr) 1992-01-16 1993-01-19 Methodes et compositions pour le traitement de la maladie angiogenique

Country Status (5)

Country Link
EP (1) EP0576669A4 (fr)
JP (1) JPH06506702A (fr)
AU (1) AU3592593A (fr)
CA (1) CA2106368A1 (fr)
WO (1) WO1993013794A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1006437A3 (fr) * 1992-12-10 1994-08-30 Company S A Z Sequence nucleotidique destinee au traitement du cancer et des infections.
MX9401807A (es) * 1993-03-12 1995-01-31 Xoma Corp Usos terapeuticos de productos de proteina que incrementan lapermeabilidad/bactericidas.
US5733872A (en) * 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
AU4788396A (en) * 1995-02-16 1996-09-04 Children's Medical Center Corporation Inhibition of angiogenesis using interleukin-12
FI955489A0 (fi) * 1995-11-15 1995-11-15 Antti Aarne Ilmari Lange Foerfarande foer adaptiv Kalmanfiltrering i dynamiska system
EP2287183A1 (fr) * 2009-07-29 2011-02-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutants PF4 polypeptides exhibiting an increased anti-angiogenic activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645828A (en) * 1984-03-23 1987-02-24 Oncogen Platelet related growth regulator
AU623589B2 (en) * 1987-03-02 1992-05-21 Bristol-Myers Squibb Company Platelet related growth regulator
US5026639A (en) * 1988-01-14 1991-06-25 Nippon Mining Company, Limited Method to improve mRNA translation and use thereof for production of platelet factor-4
US5086164A (en) * 1989-01-10 1992-02-04 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
EP0541716A1 (fr) * 1990-07-27 1993-05-19 Repligen Corporation Compositions et procedes nouveaux pour le traitement des maladies angiogeniques
WO1993002192A1 (fr) * 1991-07-15 1993-02-04 Repligen Corporation Compositions pf4 et procedes d'utilisation desdites compositions

Also Published As

Publication number Publication date
AU3592593A (en) 1993-08-03
EP0576669A1 (fr) 1994-01-05
EP0576669A4 (en) 1996-05-08
JPH06506702A (ja) 1994-07-28
WO1993013794A1 (fr) 1993-07-22

Similar Documents

Publication Publication Date Title
US5284827A (en) Systemic treatment of metastatic cancer with platelet factor 4
US5112946A (en) Modified pf4 compositions and methods of use
CA2082804A1 (fr) Methodes et compositions pour le traitement des affections angiogeniques
US5800820A (en) Methods and compositions for treatment of angiogenic diseases
US5935567A (en) Cytokine IP-10 as an anti-tumor agent
NO333999B1 (no) NTP-peptider og anvendelse av slike for fremstilling av et medikament for behandling av tumorer og andre tilstander som krever fjerning eller destruksjon av celler
WO1993009799A1 (fr) Supression de la megacaryocytopoïese a l'aide de proteines inflammatoires de macrophages
EP1038011B1 (fr) Procede de production de proteines anti-angiogeniques, dont l'endostatine, l'angiostatine ou la restine, au moyen d'un systeme d'expression de la levure pichia
CA2528635A1 (fr) Traitement de tumeurs a l'aide de peptides formant des feuillets beta et d'une radiotherapie
AU2006244080C1 (en) Use of peptides derived from the growth factor AMP-18 for the treatment of mucositis
EP0643972B1 (fr) Utilisation d'un facteur-1 stimulant de colonie (CSF-1) recombinant pour la préparation d'un médicament traitant l'infection par le cytomégalovirus
CA2106368A1 (fr) Methodes et compositions pour le traitement de la maladie angiogenique
RU2164414C2 (ru) Подавление роста опухолевых клеток эктодоменом синдекана-1
AU2004285847A1 (en) Antiangiogenicpeptides for treating or preventing endometriosis
EP0594749A1 (fr) Compositions pf4 et procedes d'utilisation desdites compositions
EP1358888A1 (fr) L'Antibiotique peptidique humain LL-37/hCAP-18 est un inducteur de l'angiogénèse
US6797488B1 (en) Methods of producing anti-angiogenic proteins
CN114605501B (zh) 一种可拮抗fus蛋白rna结合活性的多肽fip-21及其应用
US8017576B2 (en) Methods and compositions to treat mucositis
EP2552940A2 (fr) Peptides pour favoriser l'angiogenèse et leur utilisation
EP1885390A2 (fr) Utilisation du facteur de croissance amp pour le traitement des lésions gastrointestinales et de la insuffisance renale aigue
KR20210127618A (ko) 섬유질환 예방 또는 치료용 재조합 융합 단백질
JP4583763B2 (ja) 切断型２４ｋＤａ塩基性線維芽細胞成長因子
JP2006519873A (ja) 血管形成を促進するための腫瘍内皮マーカー１、９、および１７の使用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead